MedsPaL is an open access/free database providing information on the **patent** and **licensing** status of patented medicines on the World Health Organization (WHO) Model List of Essential Medicines (EML) and select products under investigation for the treatment of HIV, tuberculosis and COVID-19 in low- and middle-income countries (LMICs).

**WHAT IS MEDSPAL?**
Developed by the Medicines Patent Pool (MPP), the database offers an overview of the intellectual property status of approximately **110** medicines in **130** developing countries.

**WHAT DOES MEDSPAL CONTAIN?**

**PATENT DATA**
Granted patents and pending patent applications relating to specific medicinal formulations, with:
- bibliographical details
- legal status (e.g. filed, granted, opposed, expired)
- expected expiry dates
- links to actual patent documents on Espacenet, the European Patent Office public database

**LICENCE INFORMATION**
Information on patent licences that enable generic access in LMICs:
- licences negotiated by the MPP (with links to the full licences)
- bilateral licences between originators and generics
- public commitments not to enforce patents
- compulsory licences, if publicly available

**DATA EXCLUSIVITY**
Information on data exclusivity protection from 15 countries from National regulatory authorities with expiry date.

**HOW IS MEDSPAL UPDATED?**
- automated data feeds
- online searches
- patent holder disclosures (MPP licenses, Pat-Informed, disclosures to patent offices)
- collaborations with patent experts
- collaborations with national/regional patent offices (collaboration agreements)
SEARCH VIEW - Search by keywords, products, countries and/or disease areas

MAP VIEW - Search by formulation

Data Exclusivity

Patent Information

License Information

Licence Card

Title: MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations
Type: MPP Licence
Licensor: Viiv
Countries: Afghanistan, Angola, Armenia, Bangladesh, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Show B4 more
Licensee(s): Anhui, Celltrion, Cipla, Desano, Dr. Reddy, Emcure, Hetero, Mushai, Langhua, Laurus Labs Show 7 more

Highlight countries

- With at least one patent granted/filed
- With at least one compound patent granted/filed
- Included in licence(s)

Licences

- MPP licence on adult formulations of dolutegravir (DTG) and DTG/ABC combinations
- MPP licence on paediatric formulations of dolutegravir (DTG)

Patent and Licensing Status of approx. 110 priority medicines in low- & middle-income countries
COLLABORATIONS WITH REGIONAL AND NATIONAL PATENT OFFICES

To collect and update the data in MedsPal, the MPP has signed collaboration agreements with the following regional and national patent offices:

African Regional Intellectual Property Organization (ARIPO), the Eurasian Patent Office (EAPO), the European Patent Office (EPO)

National patent offices of Argentina (INPI), Brazil (INPI), Chile (INAPI), Dominican Republic (ONAPI), Ecuador (SENADI), Egypt (EGPO), El Salvador (CNR), Peru (INDECOPI), South Africa (CIPC) and Uruguay (DNPI).

WHY MEDSPAL?

MedsPaL seeks to address the challenges faced when seeking patent information on medicines such as:

- The complexity of patent documents and patent procedures
- The technical and legal knowledge required to search and assess patent documents
- The need to go to each national patent office to check the patent status
- Electronic national patent registers not always available
- National registers may only be available in the national language and may not include patent status

WHAT IS MEDSPAL USED FOR?

The tool is widely used by key public health actors for the purposes of:

- Procurement of medicines
- Investment/supply of medicines
- Policy analysis and policy-making
- Access strategies
- Advocacy

The MPP looks forward to expanding its network of collaborating patent offices. National or regional patent offices interested in partnering may contact: medspal@medicinespatentpool.org